Predicting QTc Effects at Therapeutic and Supratherapeutic Exposure

From a Concentration-QTc Model to an Exposure-Specific Estimate

A fitted concentration-QTc relationship is useful for safety assessment only when its implications are evaluated at relevant exposures. The central calculation is the model-based mean QTc effect at a specified concentration, together with an interval that reflects uncertainty in that estimate. Results are often examined at therapeutic exposure and at a higher, supratherapeutic exposure because the latter can show whether the exposure-response relationship remains reassuring beyond the intended clinical range.

Here, the effect is the model-estimated mean, time-matched, baseline-adjusted, placebo-corrected QTc change, written \(\delta(C)\), at concentration \(C\). This is a population-average contrast under the model, not a prediction of one particular patient's ECG. The earlier material on baseline-adjusted and time-matched QTc change and on concentration-QTc models establishes how this contrast and its exposure-response relationship are formed.

This calculation assumes that the fitted model is an appropriate representation of the exposure-response relationship over the concentration range being evaluated; the contrast and concentration are defined on the intended scales; and the estimated coefficient covariance matrix reflects the model fit. For a mixed-effects analysis, the target here is the fixed-effect population mean contrast, with the model's appropriate uncertainty calculation. If concentration itself is uncertain, treating \(C^*\) as fixed does not account for that additional uncertainty.

Estimating the Effect and Its Uncertainty

Write the coefficient estimate as the vector \(\hat{\boldsymbol{\beta}}=(\hat{\beta}_0,\hat{\beta}_1)^\mathsf{T}\), and let \(\widehat{\mathrm{Var}}(\hat{\boldsymbol{\beta}})\) be its estimated covariance matrix. For a fixed concentration \(C^*\), the estimate is a linear combination of the coefficients. Its estimated variance is therefore:

The covariance term matters. An intercept and slope estimated from the same data are generally correlated, so adding their variances alone is not correct. The standard error describes uncertainty in the estimated mean effect; it is not the standard deviation of individual QTc responses.

With approximately normal estimation uncertainty, a two-sided 90% confidence interval is the estimate plus or minus 1.645 standard errors. With finite degrees of freedom, use the appropriate \(t\) critical value \(t_{0.95,df}\) instead. The upper endpoint of this two-sided 90% interval is also a one-sided 95% upper confidence bound under the same reference distribution.

The 1.645 multiplier is the large-sample normal approximation. The interpretation of a 90% confidence interval is about the long-run coverage of the interval procedure under its assumptions; it is not a 90% probability that the fixed true mean effect lies in this particular interval. An upper bound below a prespecified threshold supports excluding a mean effect at or above that threshold under the model and analysis assumptions. It does not establish that the drug has no QTc effect or that every individual effect is below the threshold.

Comparing Therapeutic and Supratherapeutic Exposures

Therapeutic and supratherapeutic concentrations should be selected to represent scientifically relevant exposure levels, not chosen simply because they make the fitted curve look reassuring. A supratherapeutic exposure may be informed by clinical pharmacokinetics, including conditions associated with increased exposure. The model-based contrast is evaluated at each concentration, and its standard error is recalculated there because the uncertainty in a slope contributes increasingly as concentration moves away from zero.

Why the Upper Bound Matters, and What It Does Not Say

A threshold-based assessment asks whether the data and model estimate are sufficiently precise to place the upper confidence bound below a prespecified level of concern. In concentration-QTc assessment, 10 ms is a commonly used reference point for evaluating the upper bound of the mean effect. It is a decision criterion in a defined assessment framework, not a biological boundary that separates harmless from harmful outcomes in every setting. The size of the point estimate, the uncertainty, the exposure range, and the broader safety context all matter.

The following short justification explains why the covariance formula is necessary. Let \(a=(1,C^*)^\mathsf{T}\). Then \(\hat{\delta}(C^*)=a^\mathsf{T}\hat{\boldsymbol{\beta}}\). For any fixed vector \(a\), the variance of a linear combination is \(a^\mathsf{T}\mathrm{Var}(\hat{\boldsymbol{\beta}})a\). Expanding that matrix product gives:

The quadratic form also makes clear why the covariance matrix must be coherent: the resulting variance cannot be negative. A negative result signals an implementation, transcription, or covariance-matrix problem rather than a meaningful negative standard error.

An upper confidence bound for the mean must not be confused with a prediction interval for one future observation. A prediction interval adds variability in individual observations (and, when relevant, between-person variability) to uncertainty in the estimated mean. That interval is usually wider. Which quantity is needed depends on the question: a threshold assessment of the modelled mean effect is not answered by an interval for an individual ECG.

Diagnostics, Alternatives, and Limitations

Before interpreting an exposure-specific upper bound, check that the target concentration is supported by the data and that the model's assumptions remain credible there. The earlier material on diagnostics for concentration-QTc model misspecification is relevant: curvature, influential observations, time-related patterns, or systematic residual trends can make a precise-looking linear-model bound misleading. A therapeutic exposure inside a well-sampled range and a supratherapeutic exposure far beyond the observed concentrations do not have equal evidential support.

• Check the concentration range. Mark the exposure values used for predictions against the observed concentration distribution. Predictions far outside that range are extrapolations and depend strongly on the assumed model form.
• Check the uncertainty calculation. Use the covariance matrix from the fitted model, including the intercept-slope covariance, and use the appropriate critical value and degrees of freedom where required.
• Check the target and estimand. Confirm that the predicted contrast is the intended time-matched, baseline-adjusted, placebo-corrected mean effect and that the exposure represents the clinical scenario being assessed.
• Check sensitivity to model choices. If plausible nonlinear forms or covariate specifications yield materially different upper bounds, the conclusion depends on model assumptions and should not be reported as robust.

The linear model is not the only possible approach. A nonlinear exposure-response model can represent a plateau or other curvature, but its prediction and uncertainty depend on the nonlinear parameter estimates and may be less stable when data are sparse. A categorical exposure analysis avoids imposing a straight-line relationship but can lose precision and does not naturally interpolate between exposure groups. Either alternative still requires a clearly defined mean contrast and an uncertainty calculation appropriate to its fitted model.

If exposure estimates are uncertain, a fixed-concentration calculation may understate total uncertainty. A model that propagates PK uncertainty, or a sensitivity analysis over plausible concentrations, may be needed; the earlier material on concentration assignment and PK uncertainty addresses that issue. Similarly, an upper confidence bound is only as reliable as the study design, ECG measurement quality, model specification, and uncertainty method. It cannot repair inadequate sampling or a poorly supported exposure range.

Common Mistake

A related mistake is to interpret an upper bound below 10 ms as proof of no effect, or as a guarantee that no individual will exceed 10 ms. It supports a narrower conclusion: under the stated model and assumptions, the upper confidence bound for the specified population mean contrast is below the assessment threshold. Other safety findings and the clinical context remain relevant.